PTAB Institutes IPR Proceedings Against Mayne Pharma’s Antifungal Formulation Patent, PTAB Litigation Blog
The PTAB instituted an IPR on claims of Mayne Pharma International Pty Ltd.’s (“Mayne”) U.S. Patent No. 6,881,745 B2 covering formulations of azole antifungals in IPR2016-01186. In response to Merck Sharp & Dohme Corp.’s (“Merck”) Petition, the PTAB instituted review of some claims on anticipation grounds, and of all challenged claims on the grounds of obviousness.
Read the full article at ptablitigationblog.com.